Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

757.39 +25.60 (+3.50%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
Intuitive Surgical Plunges After Saying Tariffs Impact 'Could Be Material'
Intuitive Surgical stock plunged late Tuesday on worries about potential tariffs. The impact "could be material." 
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1. 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Reports suggest Novo Nordisk has asked the FDA to approve its oral semaglutide, two years after reporting a Phase 3 win. 
Via Investor's Business Daily
Exposures Product Safety
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Via The Motley Fool
Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry
The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results. 
Via Stocktwits
Exposures Product Safety
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline
Pfizer Inc (NYSE:PFE) is scheduled to release its first quarter 2025 earnings on 29 April. 
Via Benzinga
Topics Earnings
Exposures Financial
ETFs Last Week: Thematic ETFs Gleamed Against Market Gloom
Last week, thematic and leveraged ETFs performed well, such as DJTU, LLYX, NFXL, DECO, and MSTY, despite market concerns. Tech sector was hit by geopolitical tension and hawkish central bank comments.... 
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Via The Motley Fool
US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert
U.S. stock futures declined on Monday after a holiday-shortened week that ended with a mixed close on Thursday. 
Via Benzinga
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Dow Dips Over 500 Points, Down For 3rd Straight Session As UnitedHealth Tanks: Greed Index Remains In 'Extreme Fear' Zone
U.S. stocks end lower, Dow falls over 500 points. Fear & Greed index remains in Extreme Fear zone. Eli Lilly & Co. sees sharp rally on trial results. 
Via Benzinga
Topics Stocks
Exposures US Equities
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Via The Motley Fool
Stocks Finish The Week Lower Despite Solid Start To Earnings Season
After a volatile couple of weeks in which stocks fluctuated wildly, things seemed to have settled down a bit this week, although the major indexes finished mostly lower. 
Via Talk Markets
Topics ETFs Stocks / Equities
Is Eli Lilly Stock a Buy Right Now?
The pharmaceutical sector could be the next industry to face sweeping tariffs from the Trump administration. 
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Benzinga Bulls And Bears: Netflix, UnitedHealth, Eli Lilly — And Market Volatility Continues
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Market Monitor April 18 ( Eli Lilly, Netflix UP, United Health Group, Manpower DOWN)
Wall Street Mostly Lower Amid Trump-Fed Tensions, Nvidia’s Continued Slide 
Via Chartmill
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
Stay informed with the top movers within the S&P500 index on Thursday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035. 
Via Benzinga
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025. 
Via Benzinga
Which S&P500 stocks have an unusual volume on Thursday?
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Thursday. Stay informed about the market activity below. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.